Skip to main content

Table 3 Observed sustained virological response rates in subgroups at 12 weeks (SVR12) after completing therapy with daclatasvir and sofosbuvir, with or without ribavirin

From: The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

Subgroups   SVR12
As-treated Intent-to-treat
% Fraction % Fraction
Genotypea 1 98 171/174 92 171/186
3 94 33/35 85 33/39
Other 94 15/16 88 15/17
Cirrhosis None or compensated 100 93/93 99 93/94
Decompensated 95 126/132 85 126/148
Prior treatment Naive 99 75/76 88 75/85
Experienced 99 144/149 92 144/157
Ribavirin Without 96 157/163 88 157/178
With 100 62/62 97 62/64
Overall   97 219/225 90 219/242
  1. aGenotype for the 6 patients without a sustained virologic response 12 weeks after the end of treatment: 1a, 1b (n = 2), 3a (n = 2) and 5a